

Development of Treatment Drugs for Obesity using Concomitant Administration of Microbiome Consortia

KoBiolabs, Inc.



METABOLIC	Candidate
Product Type	Microbiome therapeutics (Multi-strain Consortia)
Indication	Obesity
Target	Microbial community
MoA(Mechanism of Action)	Body weight loss via modulation of glucose metabolism, anti-inflammatory effect, and reconstruction of obese dysbiosis and impaired gut permeability
Competitiveness	<p>First-in-class oral anti-obesity therapeutics based on triple-strain consortia</p> <ul style="list-style-type: none"> • Efficacy: Triple strain consortia with verified anti-obesity efficacy • Safety: Safe human-derived commensal microbial strains • Oral drug: Advantages for patient compliance and drug administration convenience • No drug resistance: Suitable for chronic metabolic diseases such as obesity requiring long-term use
Development Stage	Candidate
Route of Administration	Oral